Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

By sjmartinez • April 1, 2025

Singh S, Nguyen JD, Fudman DI, Gerich ME, Shah SA, Hudesman D, McConnell RA, Lukin DJ, Flynn AD, Hwang C, Sprung B, Gaidos JKJ, Mattar MC, Rubin DT, Hashash JG, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy JD, Ananthakrishnan AN, Cross RK, Rodriguez Gaytan JR, Gurrola ES, Patel S, Siegel CA, Melmed GY, Weaver SA, Power S, Zou G, Jairath V, Hou JK. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615. PMID: 40164445.

Tags: Cedars Sinai DoM, Crohn’s disease, Digestive Diseases, immunotherapy, inflammatory bowel disease, Publications

Impact and management of warm autoimmune haemolytic anaemia associated with systemic lupus erythematosus

Pons-Estel GJ, Mosca M, Wallace DJ, Zazzetti F, Leon A, Noël W, Pierce A, Ebrahim T, Murakhovskaya I. Impact and management of warm autoimmune haemolytic[...]

Sudden cardiac arrest: Limitations in risk-stratification and treatment, and the potential for digital technologies and artificial intelligence to improve prediction and outcomes

Srivats S, Zghyer F, Shahrori Z, Albert C, Al-Khatib SM, Chugh S, Etheridge SP, Goldberger ZD, Gopinathannair R, Lakkireddy D, Morin DP, Perez MV, Rottmann[...]

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats[...]